More and more science-based projects are being shared across silos, networks, and organizations. At the same time, biomedical knowledge is expanding rapidly, but the existing drug-discovery process is unable to keep pace. The industry needs to fix what is broken, and the solution, our experts say, is in the evolution of a virtual business model.
The greatest benefit is obviously vastly accelerated therapy development and being able to facilitate and accelerate both R&D in drugs and other therapies.
Commerce has gone to an Internet-based supply-chain workflow management model, and it’s just a small step to make the equivalent move in a science-based industry.